Role of Pegylated Interferon-α-2a and Ribavirin Concentrations in Sustained Viral Response in HCV/HIV-Coinfected Patients
- 2 July 2008
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 84 (5) , 573-580
Abstract
The effect of simultaneous plasma concentrations of pegylated interferon‐α‐2a (pegIFN‐α‐2a) and ribavirin (Rbv) on viral response has not been addressed to date. Hepatitis C virus (HCV)/human immunod...Keywords
This publication has 33 references indexed in Scilit:
- Hepatitis C virus RNA: Dinucleotide frequencies and cleavage by RNase LVirus Research, 2007
- Impact of NS5A Sequences of Hepatitis C Virus Genotype 1a on Early Viral Kinetics during Treatment with Peginterferon‐α2a plus RibavirinThe Journal of Infectious Diseases, 2007
- Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International PanelAIDS, 2007
- Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha‐2b and ribavirinJournal of Viral Hepatitis, 2006
- Pharmacodynamics of PEG-IFN α differentiate HIV/HCV coinfected sustained virological responders from nonrespondersHepatology, 2006
- 82 Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): Interim results of a randomised controlled trialJournal of Hepatology, 2006
- Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responderJournal of Medical Virology, 2006
- New Kinetic Models for the Hepatitis C Virus *Hepatology, 2005
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Classification of chronic viral hepatitis: a need for reassessmentJournal of Hepatology, 1991